Lipid-based amphotericin B for the treatment of fungal infections

Pharmacotherapy

Volumn 19, Issue 3, 1999, Pages 306-323

  Slain, Douglas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; LIPID EMULSION;

ANEMIA; ANTIFUNGAL ACTIVITY; CHILL; DATA ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG TOLERANCE; FEVER; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; MYCOSIS; NAUSEA; NEPHROTOXICITY; PROPHYLAXIS; REVIEW; RIGOR; VOMITING;

EID: 0033046042     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.4.306.30934     Document Type: Review

References (132)

1. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988;11(suppl A):411-26.
2. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
3. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science 1994;264:371-3.
4. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;30:121-9.
5. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
6. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24:1068-78.
7. Bennett JE. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:2306-11.
8. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991;9:77-84.
9. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098-1103.
10. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
11. Patterson TF, Kirkpatrick WR, White M, et al. Therapy of invasive aspergillosis: disease spectrum, treatment practices, and outcomes [abstr]. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1996.
12. Bristol-Myers Squibb Co. Fungizone (amphotericin B) package insert. Princeton, NJ;September 1993.
13. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991;28(suppl B):27-38.
14. Gallis HA, Drew RH, Pichard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12(2):308-29.
15. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997;41:1392-5.
16. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 1998;26:334-8.
17. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole vs. amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
18. Clements JS, Peacock JE. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990;88(suppl 5):22N-7.
19. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64.
20. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporin after marrow transplantation. Transplantation 1983;35:211-15.
21. Tatro DS, ed. Drug interaction facts. St. Louis: Facts and Comparisons, 1994:229.
22. Kucers A, Crowe SM, Grayson ML, Hoy JF, eds. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs, 5th ed. Oxford: Butterworth-Heinemann, 1997:1245-94.
23. Maddux MS, Barriere SL. A review of complications of amphotericin-B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1980;14:177-81.
24. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis 1987;156:784-9.
25. Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumor necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994;34:975-87.
26. Chia JKS, McManus EJ. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990;34:906-8.
27. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987;56(6):803-8.
28. Oldfield EC, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990;34:1402-6.
29. Grasela TH, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:341-8.
30. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991;51(4);925-7.
31. Branch RA. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
32. Godwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
33. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983;8:17-42.
34. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23(4):279-91.
35. Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 1997;41:1275-80.
36. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis 1993;17(suppl 2):S501-6.
37. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.
38. Fielding RM. Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet 1991;21(3):155-64.
39. Hwang KJ. Liposome pharmacokinetics. In Ostro MJ, ed. Liposomes: from biophysics to therapeutics. New York: Marcel Dekker, 1987:109-56.
40. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-87.
41. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371-81.
42. Graybill JR, Craven PC, Taylor RL, et al. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982;145:748-52.
43. Taylor RL, Williams DM, Craven PC, et al. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 1982;125:610-11.
44. Juliano R, Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Lasi L. Pharmacokinetic and therapeutic consequences of liposomal drug delivery: fluorodeoxyuridine and amphotericin B as examples. Biol Cell 1983;47:39-46.
45. Lopez-Berestein G, Mehta R, Hopfer RL, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983;147:939-45.
46. Lopez-Berestein G, Mehta R, Hopfer R, et al. Effects of sterols on the therapeutic efficacy of liposomal-amphotericin B in murine candidiasis. Cancer Drug Delivery 1983;1:37-41.
47. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533-6.
48. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6.
49. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3(3):451-71.
50. Sculier JP, Bron D, Coune F, Meunier F. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis 1989;8:903-6.
51. Sculier JP, Counne A, Meunier F, et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988;24:527-38.
52. Patterson TF, Miniter P, Dijkstra J, Szoka FC, Ryan JL, Andriole VT. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 1989;159:717-24.
53. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994;38:518-22.
54. Vita E. Intralipid in prophylaxis of amphotericin B nephrotoxicity. Ann Pharmacother 1994;28:1182-3.
55. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-41.
56. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
57. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
58. Sorkine P, Nagar H, Weinbroum A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 1996;24:1311-15.
59. Trissel LA. Amphotericin B does not mix with fat emulsion [letter]. Am J Health-Syst Pharm 1995;52:1463-4.
60. Heyman MB, Storch S, Ament ME. The fat overload syndrome. Report of a case and literature review. Am J Dis Child 1981;135:628-30.
61. Schoffski P, Freund M, Wunder R, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 1998;317:379-84.
62. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987;3(2):123-93.
63. Storm G, van Etten E. Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur J Clin Microbiol Infect Dis 1997;16:64-73.
64. Wasan KM, Lopez-Berestein G. Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis 1997;16:81-2.
65. Wasan KM, Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis 1996;23:1126-38.
66. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother 1991;28(suppl B):39-48.
67. Fischer GW, Hunter KW, Wilson SR, Mease AD. Diminished bacterial defenses with intralipid. Lancet 1980;2(8199):819-20.
68. Bakker-Woudenberg IAJM, ten Kate MT, Storm G, van Etten EWM. Administration of liposomal agents and the phagocytic function of the mononuclear phagocyte system. Int J Pharmaceutics 1998;162:5-10
69. van Etten EWM, ten Kate, MT, Snijders SV, Bakker-Woudenberg IAJM. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob Agents Chemother 1998;42:1677-81.
70. Storm G, Nassander UK, Steerenberg PA, Roerdink FH, De Jong WH, Crommelin DJA. Studies on the mode of action of doxorubicin-liposomes. In: Fidler IJ, Lopez-Berestein G, eds. Liposomes in the therapy of infectious diseases and cancer. New York: Alan R. Liss, 1989:105-16.
71. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G. Phagocyte transport as a mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 1994;40:256-64.
72. Juliano RL, Grant CWM, Barber KR, Kalp MA. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987;31:1-11.
73. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(suppl 5):S3-7.
74. Proffitt RT, Adler-Moore J, Fujii G, Satorius A, Lee MJA, Bailey A. Stability and mode of action of AmBisome (liposomal amphotericin B). J Controlled Release 1994;28:342-3
75. Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998;42;767-71.
76. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107(2):271-82.
77. Cleary J, Chapman S. Cytokine expression by amphotericin B (AMB) formulations [abstr]. Proceedings of the 33rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1993.
78. Wasan KM, Lopez-Berestein G. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann NY Acad Sci 1994;730:93-106.
79. Hellmann A, Radowska D, Trocha H, et al. A pharmacokinetic study of Abelcet (amphotericin B lipid complex) in patients with definite or probable systemic fungal infections [abstr]. Proceedings of the 13th congress of the International Society for Human and Animal Mycology, Salsomaggiore, Parma, Italy, June 8-13, 1997.
80. Grasela D, Echevarria J, Summerill R, et al. Pharmacokinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC) or Fungizone, in adults with mucocutaneous leishmaniasis [abstr]. In: Programs and abstracts of the 33rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1993.
81. Liposome Company. Abelcet (amphotericin B lipid complex injection) package insert. Princeton, NJ;October 1996.
82. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995;39:2042-7.
83. Walsh TJ, Bekersky I, Yldandi V, et al. Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1995.
84. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
85. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
86. Walker RC, Hiemenz JW. Amphotericin B lipid complex in systemic mycoses refractory to amphotericin B [abstr]. Proceedings of the 31st annual meeting of the American Society of Clinical Oncology, Los Angeles, May 23, 1995.
87. Wingard JR, Walker RC. Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses [abstr]. In: Proceedings of the 36th annual meeting and exposition of the American Society of Hematology, Nashville, TN, December 5, 1994.
88. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [abstr]. In: Programs and abstracts of the 34th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1994.
89. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B [abstr]. In: Proceedings of the 37th annual meeting and exposition of the American Society of Hematology, Seattle, WA, December 5, 1995.
90. Lister J. Amphotericin B lipid complex in the management of serious systematic mycoses in patients intolerant to amphotericin B therapy [abstr]. In: Proceedings of the 36th annual meeting and exposition of the American Society of Hematology, Nashville, TN, December 5, 1994.
91. Anaissie EJ, White MH, Uzun O, et al. Amphotericin B lipid complex versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstr]. In: Programs and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1995.
92. Sharkey PA, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
93. Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-8.
94. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(suppl B):83-91.
95. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
96. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18.
97. Walsh T, Bodensteiner D, Hiemenz J, et al. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients [abstr]. In: Programs and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1997.
98. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71.
99. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
100. Bowden RA, Cays M, Gooley T, Mamelok RD, Burik JV. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infection after marrow transplant. J Infect Dis 1996;173:1208-15.
101. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
102. White MH, Anaissie EJ, Knuse S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-42.
103. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998;26:461-7.
104. Herbrecht R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997;16:74-80.
105. Walsh TJ, Hiemenz J. Lipid formulations of amphotericin B: recent developments in improving the therapeutic index of a gold standard. Infect Dis Clin Pract 1998;7(suppl 1):S16-27.
106. Clemons KV, Stevens DA. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998;42:899-902.
107. Sharkey PK, Lipke R, Renteria A, et al. Amphotericin B lipid complex (ABLC) in the treatment of coccidioidomycosis [abstr]. In: Programs and abstracts of the 31st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1991.
108. Hostetler JS, Caldwell JW, Johnson RH, et al. Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD) [abstr]. In: Programs and abstracts of the 32nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1992.
109. Anaissie EJ, Ramphal R, Horwith G. Efficacy and safety of amphotericin B lipid complex injection (Abelcet) in the treatment of patients with fusariosis [abstr]. Proceedings of the 38th annual meeting and exposition of the American Society of Hematology, Orlando, FL, December 9, 1996.
110. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis: therapy with amphotericin B lipid complex. Arch Intern Med 1996;156:337-9.
111. Harten P, Baron Y, Euler HH. Liposomal amphotericin B therapy in disseminated histoplasmosis. Arch Intern Med 1995;155:1556.
112. Weng DE, Wyndham HW, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998;26:601-5.
113. Naguib MT, Huycke MM, Pederson JA, Pennington LR, Burton ME, Greenfild RA. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis 1995;26(2):381-4.
114. Reed MD, Goldfarb J, Blumer JL. Anti-infective therapy In: Jenson HB, Baltimore RS, eds. Pediatric infectious diseases: principles and practice. Norwalk, CT: Appleton & Lange, 1995:240-3.
115. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management. Drug Saf 1992;7:323-63.
116. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8.
117. Shulman RJ, Langston C, Schanler RJ. Pulmonary vascular lipid deposition after administration of intravenous fat to infants. Pediatrics 1987;79:99-102.
118. Anonymous. Pulmonary arterial lipid deposition after intravenous lipid infusions in neonates. Nutr Rev 1981;39:271-3.
119. Puntis JWL, Rushton DI. Pulmonary intravascular lipid in neonatal necropsy specimens. Arch Dis Child 1991;66:26-8.
120. Scarcella A, Pasquariello MB, Gugliano B, Vendemmia M, De Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17:146-8.
121. Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998;26:11-15.
122. Gubbins PO, Bowman JL, Penzak SR. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacotherapy 1998;18(3):549-64.
123. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
124. Lam HH, Althaus BL. Antifungal prophylaxis in bone marrow transplant. Ann Pharmacother 1995;29:921-4.
125. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infection in allogeneic marrow transplantation. Am J Med 1991;91:484-92.
126. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
127. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-14.
128. Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-82.
129. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant Proc 1995;27:1195-8.
130. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics, 1998.
131. Boogaerts M, Tormans G, Maes E, et al. Cost-effectiveness analysis of AmBisome (AMB) vs. amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children [abstr]. Blood 1996;88(suppl 1):501a.
132. Persson U, Tennvall GR, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992;2:500-8.